ENTA
Enanta Pharmaceuticals, Inc
stockNASDAQ
enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta's lead protease inhibitor, paritaprevir, is part of abbvie's recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 11.18 | 2026-10-14 | +1.16% | 3.963 |
| 1M | 12.11 | 2026-09-21 | -6.61% | 0.835 |
| 3M | 13.42 | 2026-07-21 | -15.72% | 1.073 |
| 6M | 13.24 | 2026-04-21 | -14.58% | 0.268 |
| 1Y | 11.01 | 2025-10-21 | +2.73% | 0.842 |
| 2Y | 12.64 | 2024-10-21 | -10.52% | — |
| 5Y | 72.12 | 2021-10-21 | -84.32% | 0.965 |
Enanta Pharmaceuticals, Inc (NASDAQ:ENTA) stock price today is $11.31, and today's volume is 121,730. ENTA is down 3.085% today. The 30 day average volume is 268,220. ENTA market cap is $329.41M with 29.13M shares outstanding.